Learning Objectives:

1.  To define the role of PD-L1 in selecting patients for front line immunotherapy

2.  To evaluate the potential of TMB as a biomrker for immunotherapy

3.  To review the role chemo sparing regimen in treating lung cancer

Session date: 
Monday, July 13, 2020 - 12:00pm to 1:00pm
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Hossein Borghaei, DO, MS